Nanotechnology, Bioequivalence On Pharmaceutical Science Panel Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
Need for guidance on orally disintegrating tablets as a separate dosage form also on July 22-23 agenda.
You may also be interested in...
Nanotech Boom Presents Challenges For Both Industry, Regulators
FDA is ready to protect public from unsafe nano-materials despite challenges of regulating nanotech development, the agency says at Baltimore roundtable.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.